{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6"],"submitter":["Baum SJ"],"funding":["Amgen Inc"],"pubmed_abstract":["<h4>Objective</h4>We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively identified 2018 American College of Cardiology/American Heart Association guideline very high-risk (VHR) ASCVD criteria; (2) utilization of guideline-directed lipid-lowering therapy (LLT); and (3) the proportion of patients with persistent low-density lipoprotein cholesterol (LDL-C) elevations despite statin and/or ezetimibe use.<h4>Methods</h4>A retrospective cohort study using the Prognos LDL-C database linked to IQVIA longitudinal medical and prescription claims databases. The study period was from January 01, 2011, to November 30, 2019 and the index period was "],"journal":["American journal of preventive cardiology"],"pagination":["100177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8315617"],"repository":["biostudies-literature"],"pubmed_title":["Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States."],"pmcid":["PMC8315617"],"pubmed_authors":["Nunna S","Habib M","Baum SJ","Philip K","Wang X","Wade RL","Rane PB","Sun K"],"additional_accession":[]},"is_claimable":false,"name":"Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.","description":"<h4>Objective</h4>We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively identified 2018 American College of Cardiology/American Heart Association guideline very high-risk (VHR) ASCVD criteria; (2) utilization of guideline-directed lipid-lowering therapy (LLT); and (3) the proportion of patients with persistent low-density lipoprotein cholesterol (LDL-C) elevations despite statin and/or ezetimibe use.<h4>Methods</h4>A retrospective cohort study using the Prognos LDL-C database linked to IQVIA longitudinal medical and prescription claims databases. The study period was from January 01, 2011, to November 30, 2019 and the index period was ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2026-07-16T11:16:17.492Z","creation":"2026-07-09T10:55:37.552Z"},"accession":"S-EPMC8315617","cross_references":{"pubmed":["34327500"],"doi":["10.1016/j.ajpc.2021.100177"]}}